World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
84
Citations
23514
World Ranking
1393
National Ranking
92

Peter Brossart publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Peter Brossart sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 465 publications — 87th percentile

87% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Peter Brossart D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Peter Brossart sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 84 D-Index — 73rd percentile

73% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Peter Brossart is affiliated with the University Hospital Bonn in Germany. Their research focuses extensively on medicine, with significant contributions bridging oncology, immunology, rheumatology, hematology, and molecular biology. The core of their work centers on cancer immunotherapy and biomarkers, immunotherapy and immune responses, multiple myeloma treatments, immune cell function and interaction, CAR-T cell therapy research, vasculitis and related conditions, and spondyloarthritis studies and treatments.

Brossart has coauthored numerous publications, frequently collaborating with researchers such as Valentin Sebastian Schäfer, Charlotte Behning, Annkristin Heine, Pantelis Karakostas, and Tobias A.W. Holderried.

Their recent published papers include the following:

  • The Role of Antigen Spreading in the Efficacy of Immunotherapies, 2020, Clinical Cancer Research
  • G-quadruplexes: a promising target for cancer therapy, 2021, Molecular Cancer
  • Clinical and immunological effects of mRNA vaccines in malignant diseases, 2021, Molecular Cancer
  • Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire, 2020, Nature Reviews Clinical Oncology
  • High-risk additional chromosomal abnormalities at low blast counts herald death by CML, 2020, Leukemia

Brossart has published in a range of scientific venues, showing consistent contribution to:

  • Annals of the Rheumatic Diseases
  • Leukemia
  • Blood
  • Frontiers in Immunology
  • Ultraschall in der Medizin - European Journal of Ultrasound

The main fields of their studies cover medicine broadly, with subfields as listed:

  • Oncology
  • Immunology
  • Rheumatology
  • Hematology
  • Molecular Biology

The specific topics addressed in their research include:

  • Cancer Immunotherapy and Biomarkers
  • Immunotherapy and Immune Responses
  • Multiple Myeloma Research and Treatments
  • Immune Cell Function and Interaction
  • CAR-T cell therapy research
  • Vasculitis and related conditions
  • Spondyloarthritis Studies and Treatments

Best Publications

  • Retraction: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids.

    Alexander Kugler;Gernot Stuhler;Peter Walden;Gerhard Zöller

  • Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells.

    Peter Brossart;Stefan Wirths;Gernot Stuhler;Volker L. Reichardt

  • Identification of HLA-A2–Restricted T-Cell Epitopes Derived From the MUC1 Tumor Antigen for Broadly Applicable Vaccine Therapies

    Peter Brossart;Kathrin S. Heinrich;Gernot Stuhler;Lars Behnke

  • G-quadruplexes: a promising target for cancer therapy.

    Nils Kosiol;Stefan Juranek;Peter Brossart;Annkristin Heine

  • Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation.

    Richard F Schlenk;Sabine Kayser;Lars Bullinger;Guido Kobbe

  • Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.

    Uwe Platzbecker;Giuseppe Avvisati;Laura Cicconi;Christian Thiede

  • Her-2/neu-derived Peptides Are Tumor-associated Antigens Expressed by Human Renal Cell and Colon Carcinoma Lines and Are Recognized by in Vitro Induced Specific Cytotoxic T Lymphocytes

    Peter Brossart;Gernot Stuhler;Thomas Flad;Stefan Stevanovic

  • Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells.

    Susanne M. Schmidt;Kerstin Schag;Martin R. Müller;Markus M. Weck

  • Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses.

    Madeleine M. Hipp;Norbert Hilf;Steffen Walter;Daniela Werth

  • The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo

    Annkristin Heine;Stefanie Andrea Erika Held;Solveig Nora Daecke;Stephanie Wallner

  • Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

    Rüdiger Hehlmann;Michael Lauseker;Susanne Saußele;Markus Pfirrmann

  • Dendritic Cell Immunogenicity Is Regulated by Peroxisome Proliferator-Activated Receptor γ

    Alessio Nencioni;Frank Grünebach;Anke Zobywlaski;Claudio Denzlinger

  • Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients.

    Jan Wierecky;Martin R. Müller;Stefan Wirths;Edith Halder-Oehler

  • Proteasome inhibitors: antitumor effects and beyond.

    A Nencioni;F Grünebach;F Patrone;A Ballestrero

  • The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes.

    Peter Brossart;Anya Schneider;Patricia Dill;Theodora Schammann

  • RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.

    V I Gaidzik;V Teleanu;E Papaemmanuil;D Weber

  • PPAR-γ agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF-κB pathways

    Silke Appel;Valdete Mirakaj;Anita Bringmann;Markus M. Weck

  • Monocyte-derived dendritic cells are permissive to the complete replicative cycle of human cytomegalovirus.

    S. Riegler;H. Hebart;H. Einsele;P. Brossart

  • Intradermal Vaccinations With RNA Coding for TAA Generate CD8+ and CD4+ Immune Responses and Induce Clinical Benefit in Vaccinated Patients

    Susanne M Rittig;Maik Haentschel;Katrin J Weimer;Annkristin Heine

  • Generation of Functional Human Dendritic Cells From Adherent Peripheral Blood Monocytes by CD40 Ligation in the Absence of Granulocyte-Macrophage Colony-Stimulating Factor

    Peter Brossart;Frank Grünebach;Gernot Stuhler;Volker L. Reichardt

  • The use of dendritic cells in cancer immunotherapy

    Alessio Nencioni;Frank Grünebach;Susanne M. Schmidt;Martin R. Müller

Frequent Co-Authors

Frank Grünebach
Frank Grünebach University of Tübingen
Lothar Kanz
Lothar Kanz University of Tübingen
Alessio Nencioni
Alessio Nencioni University of Genoa
Arnold Ganser
Arnold Ganser Hannover Medical School
Hartmut Goldschmidt
Hartmut Goldschmidt University Hospital Heidelberg
Hartmut Döhner
Hartmut Döhner University of Ulm
Hans-Georg Rammensee
Hans-Georg Rammensee University of Tübingen
Richard F. Schlenk
Richard F. Schlenk University Hospital Heidelberg
Anna Jauch
Anna Jauch Heidelberg University
Glen Kristiansen
Glen Kristiansen University Hospital Bonn

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing Immunology in the USA opens doors to various related healthcare careers, many of which offer flexible online learning options. For those interested in expanding their nursing skills, exploring the best online BSN programs for non nurses is a great place to start. These programs cater to individuals switching careers and provide a direct path to becoming a registered nurse.

If you are looking to fast-track your nursing career, consider accelerated BSN programs for non nurses. These intensive courses significantly reduce the time required to earn a Bachelor of Science in Nursing, making it easier to enter the workforce sooner.

For those seeking foundational roles in nursing, accredited programs matter. Finding accredited LPN programs easy to get into can help jump-start your career in licensed practical nursing with accessible options that balance quality and admission ease.

Advanced roles such as Nurse Practitioner also have online pathways. Understanding what is the easiest NP program can assist in selecting programs that offer practical curricula and manageable entry requirements, helping you achieve higher-level nursing roles.

Best Scientists Citing Peter Brossart

Trending Scientists

Recently Published Articles